Literature DB >> 10523847

Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion.

I Kuzmin1, L Geil, H Ge, U Bengtsson, F M Duh, E J Stanbridge, M I Lerman.   

Abstract

Several tumor suppressor genes were shown to be inactivated by a process involving aberrant de novo methylation of their GC-rich promoters which is usually associated with transcriptional repression. The mechanisms underlying this process are poorly understood. In particular this abnormal methylation may be caused and/or maintained by either deficiency of some trans-acting factor(s) or by various malfunctions acting in cis. Here we studied the nature of aberrant methylation of the von Hippel-Lindau (VHL) disease tumor suppressor gene in a human clear cell renal carcinoma cell line, UOK 121, that contains a silent hypermethylated endogenous VHL allele. First, we transfected unmethylated VHL transgenes, driven by the VHL promoter, into UOK 121 cells. Next, to exclude possible position effects that may influence methylation of the introduced VHL genes, we transferred a single chromosome 3, carrying an apparently normal hypomethylated VHL allele into the UOK 121 cells. Finally, we created somatic cell hybrids between UOK 121 and UMRC 6 cells containing a mutant VHL-expressing hypomethylated allele. In these three experiments both the methylation of the VHL promoter and the transcriptional status of the introduced and endogenous VHL alleles remained unchanged. Our results demonstrate that the putative trans-acting factors present in the UOK 121 and UMRC 6 cells are unable to induce changes in methylation pattern of the VHL alleles in all cell lines and hybrids studied. Taken together, the results indicate that cis-specific local features are pivotal in maintaining and perpetuating aberrant methylation of the VHL CpG island. Contribution of some putative trans-acting factors cannot be excluded during a period when the aberrant VHL methylation pattern was first generated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523847     DOI: 10.1038/sj.onc.1202959

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Epigenetic gene silencing in cancer.

Authors:  B Tycko
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 2.  Microcell-mediated chromosome transfer (MMCT): small cells with huge potential.

Authors:  Aideen M O Doherty; Elizabeth M C Fisher
Journal:  Mamm Genome       Date:  2003-09       Impact factor: 2.957

3.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.

Authors:  K Dreijerink; E Braga; I Kuzmin; L Geil; F M Duh; D Angeloni; B Zbar; M I Lerman; E J Stanbridge; J D Minna; A Protopopov; J Li; V Kashuba; G Klein; E R Zabarovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

4.  Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.

Authors:  Goran Micevic; Nicholas Theodosakis; Janis M Taube; Marcus W Bosenberg; Nemanja Rodić
Journal:  Melanoma Res       Date:  2017-04       Impact factor: 3.599

Review 5.  Methylation matters.

Authors:  J F Costello; C Plass
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

6.  UV-induced proteolysis of RNA polymerase II is mediated by VCP/p97 segregase and timely orchestration by Cockayne syndrome B protein.

Authors:  Jinshan He; Qianzheng Zhu; Gulzar Wani; Altaf A Wani
Journal:  Oncotarget       Date:  2017-02-14

7.  Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma.

Authors:  Hui Liu; Jing Huang; Jin Wang; Shuguang Jiang; Alexis S Bailey; Devorah C Goldman; Markus Welcker; Victoria Bedell; Marilyn L Slovak; Bruce Clurman; Mathew Thayer; William H Fleming; Elliot Epner
Journal:  J Exp Med       Date:  2008-07-14       Impact factor: 14.307

8.  Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.

Authors:  Boban Stanojevic; Vladimir Saenko; Lidija Todorovic; Nina Petrovic; Dragan Nikolic; Vladan Zivaljevic; Ivan Paunovic; Masahiro Nakashima; Shunichi Yamashita; Radan Dzodic
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.